Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders

Inclusion criteria

• ✓. Male or female \> 6 months of age at screening visit
• ✓. Clinical diagnosis of a genetic skin disorder at the screening visit, ideally with genetic or histological confirmation.
• ✓. Must have had the gene with one or more variants identified by genotyping. If the genotype has not been performed or has not been performed at a CLIA-approved laboratory, be willing to provide a sample (saliva, buccal swab, blood) for genetic testing before starting the dupilumab.
• ✓. Average Itch Numerical Rating Scale (NRS) ≥ 4 and Worst Itch NRS of at least 5 during the previous 7 days (self-reported if \>8 years old; proxy reported if under 8 years)
• ✓. Must be willing to provide information weekly about Average and Worst Itch/self- or proxy-assessed severity and wear the sensor device to track itch and sleep weekly throughout the first 24 weeks of the trial (Parts A and B).
• ✓. Must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.
• ✓. Subject, parent/caregiver or legal guardians, as appropriate, are able to understand and complete the study requirements and study-related questionnaires

Exclusion criteria